Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MDM4 | O15151 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487948 | 1.00 | KMT2A (0.60) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL29401303 | 1.00 | KMT2A (0.60) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL29528781 | 1.00 | KMT2A (0.60) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL178805 | 1.00 | KMT2A (0.60) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL3197099 | 0.94 | MDM2 (0.54) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL29398472 | 0.93 | KMT2A (0.54) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL29401297 | 0.93 | KMT2A (0.54) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL20556494 | 0.93 | KMT2A (0.54) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL20556492 | 0.93 | KMT2A (0.54) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL178808 | 0.93 | KMT2A (0.54) | KMT2AMDM4TP53TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015023898-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130237685-A1 | LINEAR ASSEMBLIES, BRANCHED ASSEMBLIES, MACROCYCLES AND COVALENT BUNDLES OF FUNCTIONALIZED BIS-PEPTIDES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012158200-A1 | LINEAR ASSEMBLIES BRANCHED ASSEMBLIES, MACROCYCLES AND COVALENT BUNDLES OF FUNCTIONALIZED BIS-PEPTIDES | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237685-A1 | LINEAR ASSEMBLIES, BRANCHED ASSEMBLIES, MACROCYCLES AND COVALENT BUNDLES OF FUNCTIONALIZED BIS-PEPTIDES | VIP, FHIT, FGB | KMT2A 3688/4885MDM4 896/4885TP53 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.